Dublin, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026" report to their offering.

Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition.

This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of AIHA's have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AIHA include:

- Lymphoproliferative conditions:
- - CLL
- - HL
- - NHL
- Myeloproliferative conditions:
- - Multiple myeloma
- - Myelofibrosis
- - MGUS
- Autoimmune conditions:
- - RA
- - SLE
- - Polyarteritis nodosa
- Infections:
- - Pneumonia & Tuberculosis
- - Syphilis
- - Epstein-Barr
- - Chronic active hepatitis
- - Mononucleosis

Reasons to Buy:

- Able to quantify patient populations in global AIHA's market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the incidence of the subdivided types of AIHA and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on AIHA's incident population.
- Identify sub-populations within AIHA which require treatment.
- Gain an understanding of the specific markets that have the largest number of AIHA patients.

Key Topics Covered:

1. List of Tables and Figures

2. Introduction

3. Cause of the Disease

4. Risk Factors & Prevention

5. Diagnosis of the Disease

6. Variation by Geography/Ethnicity

7. Disease Prognosis & Clinical Course

8. Clinical Management of AIHA
- Transfusion therapy in AIHA

9. Key Co-morbid Conditions/Features Associated with the Disease

10. Methodology for Quantification of Patient Numbers

11. Top-Line Incidence for AIHA

12 Subtypes of AIHA patients
- Warm AIHA patients
- Cold AIHA patients
- Mixed-type AIHA patients

13. Market Forecast for AIHA
- 1st Line Treatment Options within Warm & Mixed-type AIHA
- 2nd Line Treatment Options within Warm & Mixed-type AIHA
- 1st Line Treatment Options within Cold AIHA
- 2nd Line Treatment Options within Cold AIHA
- Requirement for Blood Transfusions within AIHA

14. Methodology for Forecast Figures

15. Abbreviations used in the report

16. Patient-Based Offering

17. Online Pricing Data and Platforms

18. References

19. Appendix

For more information visit http://www.researchandmarkets.com/research/c755wk/autoimmune

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Hematology 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.